Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
18
×
boston
18
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
national top stories
deals
san francisco blog main
fda
new york blog main
san francisco top stories
investing
startups
alexion pharmaceuticals
cancer
eli lilly
hepatitis b
new york top stories
rare disease drugs
roche
third rock ventures
atlas venture
autoimmune disorders
avapritinib
biotech ipos
blackstone group
blueprint medicines
boehringer ingelheim
crispr
david goldstein
decibel therapeutics
depression
dyne therapeutics
epilepsy
essential tremor
eventide asset management
gene therapy
genentech
What
medicines
18
×
drug
genetic
therapeutics
ipo
new
research
ago
drugs
biotech
company
developing
disease
fda
million
muscle
pharma
pharmaceuticals
address
aims
approval
based
biotechs
blueprint
brings
called
cancer
candidate
deal
developer
dicerna
diseases
dyne
emerged
experimental
gene
hearing
ipos
lead
long
Language
unset
unknown
Current search:
biotech
×
medicines
×
boston
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M